Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma | Zendy

Jerónimo Rafael RodríguezCid | Zendy; Saul CamposGómez | Zendy; Vanessa García-Montes | Zendy; Manuel Magallanes-Maciel | Zendy; Rodrigo Rafael FloresMariñelarena | Zendy; Valeria Michelle FernándezGaribay | Zendy; Iván Romarico González-Espinoza | Zendy; Juan Paulo Ceja-García | Zendy; Juan Carlos Cázarez-Price | Zendy; Luis Manuel Martínez-Barrera | Zendy; Leopoldo Barriguete-Parra | Zendy; Carlos Valle | Zendy; Roberto Kuri-Exsome | Zendy; David Suárez-García | Zendy; Jorge Ignacio Gonzalez-Villanueva | Zendy; Noé Flores-Anaya | Zendy; José Antonio Acevedo-Delgado | Zendy; Alma Magdalena Astorga-Ramos | Zendy; Raquel Gerson-Cwilich | Zendy; Alberto Villalobos-Prieto | Zendy; Claudia Rodríguez-Silva | Zendy; María Fernanda Noriega-Iriondo | Zendy; Leticia Vázquez-Cortés | Zendy; Eusebio Perales-Rodríguez | Zendy; Alicia Acosta-Espinoza | Zendy; Yareni Perez-Lozano | Zendy; Daniel Capdeville-García | Zendy; Jorge Alatorre-Alexander | Zendy

Open Access

Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma

Author(s) -

Jerónimo Rafael RodríguezCid,

Saul CamposGómez,

Vanessa García-Montes,

Manuel Magallanes-Maciel,

Rodrigo Rafael FloresMariñelarena,

Valeria Michelle FernándezGaribay,

Iván Romarico González-Espinoza,

Juan Paulo Ceja-García,

Juan Carlos Cázarez-Price,

Luis Manuel Martínez-Barrera,

Leopoldo Barriguete-Parra,

Carlos Valle,

Roberto Kuri-Exsome,

David Suárez-García,

Jorge Ignacio Gonzalez-Villanueva,

Noé Flores-Anaya,

José Antonio Acevedo-Delgado,

Alma Magdalena Astorga-Ramos,

Raquel Gerson-Cwilich,

Alberto Villalobos-Prieto,

Claudia Rodríguez-Silva,

María Fernanda Noriega-Iriondo,

Leticia Vázquez-Cortés,

Eusebio Perales-Rodríguez,

Alicia Acosta-Espinoza,

Yareni Perez-Lozano,

Daniel Capdeville-García,

Jorge Alatorre-Alexander

Publication year - 2020

Publication title -

jco global oncology

Language(s) - English

Resource type - Journals

ISSN - 2687-8941

DOI - 10.1200/jgo.19.00330

Subject(s) - nintedanib , medicine , docetaxel , regimen , population , adenocarcinoma , tolerability , adverse effect , surgery , oncology , lung , chemotherapy , cancer , idiopathic pulmonary fibrosis , environmental health

The LUME-Lung 1 study has brought consistent evidence of the effective use of nintedanib in lung adenocarcinoma as a second line of treatment; however, differences among ethnicities have been found in some studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research